United Therapeutics Corporation (UTHR) SEC Filings & Earnings Calls

Settlement may involve cash outflow or other obligations; terms undisclosed.

“Settlement Agreement filed; no financial details provided.”

Aggressive buyback reduces cash reserves; potential risk if growth drivers underperform.

“Company used $477.6M cash for ASR; total $4B returned in 2.5 years.”

Competitive pressure on Tyvaso franchise from new therapies

“We believe the availability of competitive therapies negatively impacted sales of Nebulized Tyvaso, Tyvaso DPI, and Remodulin” · word for word

Inventory reserve expense increase due to supply agreement losses

“Increase in inventory reserve expense... $7.5 million related to estimated losses under a commercial supply agreement”

Competitive erosion of Tyvaso franchise

“We believe the availability of competitive therapies negatively impacted sales of Nebulized Tyvaso, Tyvaso DPI, and Remodulin for the three and six months ended June 30, 2026.” · word for word

Drug pricing reform impact

“These increased discounts impact Tyvaso DPI and Orenitram revenues, while also having an industry-wide impact on the cost of Part D drugs.” · word for word

Inventory and supply chain risk

“The Tyvaso DPI inventory reserve expense increased in the three and six months ended June 30, 2026 primarily because we recorded estimated losses of $7.5 million and $34.3 million, respectively, related to a commercial supply agreement.” · word for word

Litigation exposure

“We accrued a liability of $71.1 million during 2024, an additional $3.0 million during 2025, and an additional $1.6 million during 2026 through the second quarter, reflecting, in the aggregate, the damages and prejudgment interest amounts awarded in the final judgment [Sandoz litigation].”

Revenue decline and margin pressure from inventory reserve; competitive dynamics in inhaled prostacyclins.

“Total revenues -2% YoY; cost of sales +44% YoY with $26.8M inventory reserve; Nebulized Tyvaso -22%.”

Generic competition

“We entered into settlement agreements with certain generic drug companies permitting them to launch generic versions of Remodulin in the United States and other companies to launch generic versions of Nebulized Tyvaso and Orenitram in the United States.” · word for word

Patent litigation

“In April 2025, Liquidia initiated litigation against us alleging that Tyvaso DPI infringes a patent assigned to Liquidia.” · word for word

Drug pricing regulation

“The IRA and other healthcare reform measures that may be adopted in the future may result in additional downward pressure on the payment that we receive for any approved product.” · word for word

340B program risk

“If we are unable to curb the proliferation of abuses caused by 340B contract pharmacies, we could see increased sales at 340B ceiling prices, which could have a material adverse impact on our revenues.” · word for word

Sandoz litigation liability

“We have accrued a liability of $74.9 million in connection with such suit, reflecting the final judgment and post-judgment interest accrued through the end of March 2026, although our ultimate liability may be greater.” · word for word

Key Person Dependency

“Our founder and CEO, Dr. Martine Rothblatt, is a key and unique asset to our company.” · word for word

Concentrated Ownership

“BlackRock Inc. beneficially owns 12.5% of outstanding shares.”

Regulatory Risk

“There are few industries more heavily regulated than the biopharmaceutical and medical device industries.” · word for word

Clinical trial results may not lead to regulatory approval or commercial success.

“Positive results announced but no regulatory filing or approval mentioned.”

Litigation Risk

“During the years ended December 31, 2025 and 2024, we recorded accruals of $3.0 million and $71.1 million, respectively, related to ongoing litigation with Sandoz.” · word for word

Regulatory Risk

“We are subject to numerous federal, state, and non-U.S. laws that govern the privacy and security of health and other personal information.”

Pricing Pressure

“We pay a ten percent royalty on our net sales of Tyvaso DPI under our license agreement with MannKind.” · word for word

Dependence on Tyvaso franchise for growth; Nebulized Tyvaso declining.

“Nebulized Tyvaso revenue declined 12% in Q4.”

Nebulized Tyvaso revenue declined 11% YoY due to higher gross-to-net deductions and lower quantities sold, indicating potential competitive pressure or patient shift to DPI formulation.

“Nebulized Tyvaso revenues decreased 11% YoY to $141.8M.”

Unituxin revenue declined 22% YoY due to lower quantities sold, indicating potential competitive or demand issues in that product line.

“Unituxin revenues decreased 22% YoY to $47.9M.”

R&D expense increased 23% YoY, reflecting investment in pipeline, which could pressure near-term margins if revenue growth slows.

“Total research and development expense increased 23% YoY to $127.5M.”

Generic competition for treprostinil products

“Liquidia launched Yutrepia in June 2025, competing directly with Tyvaso DPI and Nebulized Tyvaso.”

Patent litigation outcomes

“Ongoing patent litigation with Liquidia could result in loss of exclusivity for key products.”

Pricing and reimbursement pressure

“Higher gross-to-net deductions from new PBM contracts and IRA implementation are pressuring net revenue.”

Manufacturing and supply chain risk

“Reliance on single-source suppliers for Tyvaso DPI (MannKind) and Remunity Pump (DEKA) creates concentration risk.”

Clinical trial failure risk

“Ralinepag Phase 3 ADVANCE OUTCOMES study results expected in H1 2026; failure would remove a key pipeline asset.”